NATCO Launches Generic Version of Zortress® (Everolimus Tablets 1 mg) in the U.S.

India, Oct. 31 -- NATCO Pharma Limited announced the launch of Everolimus Tablets 1 mg, a generic version of Zortress® by Novartis, under the immunosuppressant therapeutic category.

NATCO's marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International, will commence the product's launch immediately in the U.S. market.

Everolimus, an mTOR inhibitor immunosuppressant, is indicated for the prevention of organ rejection in adult patients undergoing kidney and liver transplants.

Breckenridge had earlier introduced Everolimus Tablets in 0.25 mg, 0.5 mg, and 0.75 mg strengths, with blister packs launched in July 2021 and bottle packs in June 2023.

Published by HT Digital Content Services with pe...